{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:29:09Z","timestamp":1791030549970,"version":"4.1.0"},"reference-count":19,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,1]]},"DOI":"10.1210\/jc.2008-2700","type":"journal-article","created":{"date-parts":[[2009,6,3]],"date-time":"2009-06-03T00:58:41Z","timestamp":1243990721000},"page":"2806-2811","source":"Crossref","is-referenced-by-count":73,"title":["Clinical Characteristics of Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Caused by Antithyroid Drugs"],"prefix":"10.1210","volume":"94","author":[{"given":"Jaeduk Yoshimura","family":"Noh","sequence":"first","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemitu","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Kunii","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Mukasa","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ito","sequence":"additional","affiliation":[{"name":"Ito Hospital (J.Y.N., S.Ya., S.S., M.M., Y.K., Y.N., K.M., Ko.I., Ku.I.), Tokyo 150-8308, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Drug Safety Unit (O.S., H.K., S.N., M.O., S.Yo.), Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Drug Safety Unit (O.S., H.K., S.N., M.O., S.Yo.), Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Nihojima","sequence":"additional","affiliation":[{"name":"Drug Safety Unit (O.S., H.K., S.N., M.O., S.Yo.), Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Drug Safety Unit (O.S., H.K., S.N., M.O., S.Yo.), Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Drug Safety Unit (O.S., H.K., S.N., M.O., S.Yo.), Chugai Pharmaceutical Co., Ltd., Tokyo 103-8324, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113415911800_R1","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1378\/chest.102.5.1595","article-title":"Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure.","volume":"102","author":"Stankus","year":"1992","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041113415911800_R2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1507\/endocrj.49.329","article-title":"Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves\u2019 disease treated with propylthiouracil and thiamazole.","volume":"49","author":"Wada","year":"2002","journal-title":"Endocr J"},{"key":"key\n\t\t\t\t2019041113415911800_R3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/eje.0.1420587","article-title":"Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication.","volume":"142","author":"Gunton","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113415911800_R4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2169\/internalmedicine.46.1859","article-title":"Cerebral pachyleptomeningitis associated with MPO-ANCA induced by propylthiouracil therapy.","volume":"46","author":"Abe","year":"2007","journal-title":"Intern Med"},{"key":"key\n\t\t\t\t2019041113415911800_R5","first-page":"336","article-title":"Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA): review of literature.","volume":"47","author":"Kitahara","year":"1997","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t2019041113415911800_R6","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1159\/000189164","article-title":"Antineutrophil cytoplasmic antibodies (ANCA)-associated crescentic glomerulonephritis and propylthiouracil therapy.","volume":"73","author":"Yuasa","year":"1996","journal-title":"Nephron"},{"key":"key\n\t\t\t\t2019041113415911800_R7","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/0272-6386(95)90441-7","article-title":"Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves\u2019 disease: report of three adult cases.","volume":"26","author":"Tanemoto","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041113415911800_R8","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1507\/endocrj.50.429","article-title":"Prevalence and clinico-epidemiology of familial Graves\u2019 disease in Japan based on nationwide epidemiologic survey in 2001.","volume":"50","author":"Akamizu","year":"2003","journal-title":"Endocr J"},{"key":"key\n\t\t\t\t2019041113415911800_R9","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/jc.2006-2135","article-title":"Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves\u2019 disease.","volume":"92","author":"Nakamura","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113415911800_R10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/thy.2005.15.80","article-title":"Central nervous system vasculitis caused by propylthiouracil therapy: a case report and literature review.","volume":"15","author":"Vanek","year":"2005","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113415911800_R11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1089\/thy.2000.10.595","article-title":"Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves\u2019 disease.","volume":"10","author":"Sera","year":"2000","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113415911800_R12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1001\/jama.1995.03520340064038","article-title":"Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association.","volume":"273","author":"Singer","year":"1995","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113415911800_R13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1515\/jpem-2008-210608","article-title":"Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset Graves\u2019 disease.","volume":"21","author":"Panamonta","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113415911800_R14","first-page":"4270","article-title":"High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves\u2019 disease treated with propylthiouracil.","volume":"85","author":"Sato","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113415911800_R15","first-page":"125","article-title":"Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients.","volume":"39","author":"Geffriaud-Ricouard","year":"1993","journal-title":"Clin Nephrol"},{"key":"key\n\t\t\t\t2019041113415911800_R16","first-page":"2451","article-title":"Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases.","volume":"34","author":"Chen","year":"2007","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041113415911800_R17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2265.2001.01282.x","article-title":"Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves\u2019 disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.","volume":"54","author":"Noh","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113415911800_R18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/jcem.84.1.0013","article-title":"Clinical case seminar: anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature.","volume":"84","author":"Gunton","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113415911800_R19","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/rheumatology\/ken321","article-title":"Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.","volume":"47","author":"Gao","year":"2008","journal-title":"Rheumatology (Oxford)"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/8\/2806\/9064815\/jcem2806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T17:09:16Z","timestamp":1633540156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/8\/2806\/2596617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,1]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-2700","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,1]]}}}